We are Sorry, This Page doesn't Exist

Sarepta Gets Boost From Early Trial Results on Muscular Dystrophy Treatment

Sarepta Therapeutics Inc. gained about $2.5 billion of stock market value after an early stage trial of a gene therapy showed promise in its ability to treat patients with Duchenne muscular dystrophy......»»

Category: smallbizSource: wsj17 hr. 53 min. ago

Kitov Pharmaceuticals reports "positive" results in NT219 study

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Idera Stock Down, Study on Dermatomyositis Candidate Fails

Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis. Idera Pharmaceuticals Inc IDRA announced that the phase II clinical study, eva.....»»

Category: smallbizSource: nytJun 13th, 2018

Alnylam Reports Positive Data on Lumasiran in Renal Disease

Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients. Alnylam Ph.....»»

Category: smallbizSource: nytJun 11th, 2018

Syndax Pharmaceuticals, Nektar to Study NKTR-214 in Patients with PD-1 Refractory Melanoma

Syndax Pharmaceuti.....»»

Category: futuresSource: nasdaqMay 30th, 2018

NuCana Reports First Quarter 2018 Financial Results

EDINBURGH, United Kingdom, May 23, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced financial resul.....»»

Category: earningsSource: benzingaMay 23rd, 2018

InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results

Initiated international Phase IIb study of IFX-1 in Hidradenitis Suppurativa patients Completion of primary and secondary o.....»»

Category: earningsSource: benzingaMay 17th, 2018

Shorter drug treatment OK for many breast cancer patients

Many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12, greatly reducing the risk of heart damage it sometimes can cause, a study suggests......»»

Category: topSource: foxnewsMay 16th, 2018

Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatiti.....»»

Category: personnelSource: nytMay 16th, 2018

10 Stocks Moving In Monday"s After-Hours Session

Gainers Pfenex Inc (NYSE: PFNX) shares are up 19 percent after the company announced the positive Top-Line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events. read more.....»»

Category: blogSource: benzingaMay 14th, 2018

Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

Interim Analysis for Phase 3 HONOR study of Tonmya® .....»»

Category: earningsSource: benzingaMay 14th, 2018

Catalyst Enrolls First Patient in Phase III Firdapse Study

Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis. Catalyst Pharmaceuticals, Inc. CPRX, enroled.....»»

Category: worldSource: nytApr 20th, 2018

Adamas Pharmaceuticals announces final results from GOCOVRI Phase 3 study

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 19th, 2018

Scientists Accidentally Created a ‘Mutant Enzyme’ That Could Solve The World’s Plastic Nightmare

A study of bacteria found in a Japanese recycling plant yielded unexpected results. A couple years back, scientists discovered bacteria at a Japanese recycling plant that were breaking .....»»

Category: europeSource: fortuneApr 17th, 2018

Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Pulse Biosciences stock soars to lead premarket gainers after positive study results

Shares of Pulse Biosciences Inc. rocketed 38% in premarket trade Friday, to pace all the premarket gainers, after the company revealed positive results from a study of its treatment for skin lesions. Pulse said late Thursday that .....»»

Category: topSource: marketwatchApr 13th, 2018

Incyte"s stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Shares of Incyte Corp. plunged 19% in premarket trade Friday, and Merck & Co. Inc.'s stock dropped 1.9%, after the companies said an external data monitoring comm.....»»

Category: topSource: marketwatchApr 6th, 2018

Incyte"s stock set for selloff, Merck shares drop after disappointing study results of melanoma treatment

Incyte Corp. and Merck & Co. Inc. said an external data monitoring committee (eDMC) determined that results from a phas.....»»

Category: topSource: marketwatchApr 6th, 2018

Breakingviews TV: Doc and awe

JPMorgan, Amazon and Berkshire Hathaway have named surgeon Atul Gawande as head of their new healthcare venture. Gawande’s focus on how the profit motive skews treatment for patients is spot on, but as Robert Cyran explains, he has his work cut out......»»

Category: videoSource: reuters2 hr. 53 min. ago

Eiger BioPharmaceuticals A Leader In Treatment Of Viral Hepatitis?

Eiger BioPharmaceuticals A Leader In Treatment Of Viral Hepatitis?.....»»

Category: topSource: seekingalpha8 hr. 8 min. ago